Chronic Traumatic Encephalopathy
14
4
5
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 14 trials
100.0%
+13.5% vs benchmark
7%
1 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (14)
Cohort Study of Blood Biomarkers for TES
Pilot Study Evaluating brainQuant's Ability to Detect Alterations in White Matter in Diffusion MRI, Indicative of Post-traumatic Lesions
Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease
Neurologic Stem Cell Treatment Study
Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study
Tau And Connectomics In TES Study
The DIAGNOSE-CTE Research Project
Near-Infrared Laser Stimulation for Various Neurological Conditions
Outcomes Mandate National Integration With Cannabis as Medicine
Long-term Follow-up in Severe Traumatic Brain Injury
Post-Concussion Syndrome in Professional Athletes: A Multidisciplinary Study
18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy
Amyloid and Tauopathy PET Imaging in Acute and Chronic Traumatic Brain Injury
Tau Imaging of Chronic Traumatic Encephalopathy